77 plaintiffs in Risperdal lawsuits alleging gynecomastia, or male breast growth, caused by the anti-psychotic medication have asked the judge overseeing claims in a consolidated Pennsylvania state court litigation to enforce settlement agreements reached earlier this year by the drug’s manufacturer.

According to a Motion filed on November 5th, Johnson & Johnson is refusing to stick to Risperdal settlement agreements reached on January 28, 2013, stating that the agreements should include certain co-defendants. The cases were originally filed in the Philadelphia Court of Common Pleas on behalf of men and young boys who developed male breasts after taking the atypical anti-psychotic drug used to treat schizophrenia, bipolar disorder and irritability in children with autism, among other conditions.

In addition to claims involved in January’s settlement agreement, some 250 lawsuits alleging various Risperdal side effects  are underway in the consolidated Pennsylvania proceeding. Plaintiffs in Risperdal gynecomastia lawsuits accuse Johnson & Johnson of promoting its off-label use to children, and failing to warn the general public about the medication’s association with male breast growth. Recent studies indicate that this complication may stem from Risperdal’s potential to overproduce prolactin, a hormone associated with lactation and breast development in women.

Johnson & Johnson Settles Charges over Risperdal, other Drugs with U.S. Gov’t

In addition to Risperdal gynecomastia lawsuits, Johnson & Johnson is right now facing other charges over its products; this time, from the U.S. government. Reports from Bloomberg.com indicate that the company agreed to pay $2.2 billion this month to resolve criminal and civil charges brought by the U.S. Department of Justice over the off-label promotion of Risperdal and certain other drugs. According to charges, Johnson Johnson promoted the medication off-label to elderly patients with dementia, individuals with mental disabilities and children. It remains to be seen whether this news, which was announced on November 4th, will affect claims brought over the use of Risperdal in children related to male breast growth. It is noteworthy to add, however, that the drug was not approved for pediatric uses by the U.S. Food and Drug Administration (FDA) until 2006, during which time Johnson & Johnson received multiple warnings from the federal agency against its promotion to children. Research indicates that Risperdal is prescribed to treat irritability in children with autism, and is increasingly used off-label in the treatment of ADHD.

Call a Lawyer to Find out More about Risperdal Lawsuits

Contact an attorney at Bernstein Liebhard LLP to find out more about Risperdal lawsuits alleging complications related to gynecomastia and male breast development. The Firm can be reached at (877) 779-1414.

Published November 18, 2013 by